Astrazeneca: FTSE giant lifts forecast as new drugs drive revenue growth
FTSE 100 heavyweight Astrazeneca has upgraded its full-year revenue and earnings per share (EPS) forecasts, fuelled by a surge in revenues from new medicines. Total revenue and core EPS are…